Yajin Chen
Overview
Explore the profile of Yajin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang L, Tan W, Wang M, Wei Y, Xie Z, Wang Q, et al.
Cancer Lett
. 2025 Jan;
612:217470.
PMID: 39826668
Lenvatinib is the standard first-line therapy for advanced hepatocellular carcinoma (HCC), but drug resistance significantly hampers its efficacy. Increasing evidence has shown that circular RNAs (circRNAs) play critical roles in...
2.
Jiang J, Xie Z, Wang Q, Wang B, Huang R, Xu W, et al.
BMC Public Health
. 2025 Jan;
25(1):43.
PMID: 39762826
Introduction: Gastrointestinal (GI) cancers account for over a quarter of all cancer-related deaths in the United States; however, the latest trends in their prevalence remain unclear. Methods: Data on GI...
3.
Tang H, Zhang W, Cao J, Cao Y, Bi X, Zhao H, et al.
Biosci Trends
. 2024 Dec;
18(6):505-524.
PMID: 39721704
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few...
4.
Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway
Wei Y, Yang L, Tang C, Zhuang H, Chen X, Ma X, et al.
Apoptosis
. 2024 Nov;
30(1-2):185-196.
PMID: 39522105
Cholangiocarcinoma (CCA) is known for its high aggressiveness and dismal prognosis, whose effectiveness of systemic therapy remains limited. As a multi-target drug, lenvatinib has exhibited promising effects in many solid...
5.
Chen H, Wu D, Chen Y, Shi A, Cai W, Yang X, et al.
JPEN J Parenter Enteral Nutr
. 2024 Oct;
49(1):103-111.
PMID: 39462187
Background: Diets high in antioxidants are associated with decreased prevalence of sarcopenia. This study aimed to investigate whether the composite dietary antioxidant index (CDAI) and sarcopenia have an underlying relationship....
6.
Sun J, Li Q, Bai X, Cai J, Chen Y, Chen M, et al.
Chin Med J (Engl)
. 2024 Sep;
137(21):2630-2632.
PMID: 39307924
No abstract available.
7.
Li J, Bai Y, Chen Z, Ying J, Guo Y, Fang W, et al.
Cancer Immunol Immunother
. 2024 Sep;
73(11):219.
PMID: 39235596
Background: Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MER), VEGFR-2, KIT, and MET. SAFFRON-104 (NCT03941873) was a multicohort phase Ib/II study investigating sitravatinib with/without tislelizumab, an...
8.
Hua Y, Sun Z, Xiao Y, Li H, Ma X, Luo X, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39029924
Background: Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to...
9.
Wang Q, Tan W, Zhang Z, Chen Q, Xie Z, Yang L, et al.
Apoptosis
. 2024 Jun;
29(9-10):1529-1545.
PMID: 38824477
The upregulation of programmed death ligand 1 (PD-L1) plays a crucial role in facilitating cancer cells to evade immune surveillance through immunosuppression. However, the precise regulatory mechanisms of PD-L1 in...
10.
Shao J, Gao Z, Shen Q, Zhi H, Wang X, Zheng J, et al.
J Gastrointest Surg
. 2024 May;
28(7):1089-1094.
PMID: 38703987
Purpose: The association between the age-adjusted Charlson Comorbidity Index (ACCI) and sarcopenia in patients with gastric cancer (GC) remains ambiguous. This study aimed to investigate the association between the ACCI...